<DOC>
	<DOCNO>NCT00490906</DOCNO>
	<brief_summary>The purpose study determine certain drug commonly use treat multiple sclerosis effect bone health .</brief_summary>
	<brief_title>Comparison Bone Effects With Copaxone Interferon Multiple Sclerosis</brief_title>
	<detailed_description>There 60 female patient MS University Kansas Medical Center ( KUMC ) . They split two group : Copaxone group Interferon ( Avonex , Rebif , Betaseron ) group . Each group compose 30 woman match menopausal status . Each subject give questionnaire assess risk factor low bone density . All patient determination Expanded Disability Status Scale ( EDSS ) , height weight , medical history , fracture history . All patient undergo hip spine dual x-ray absorptiometry ( DEXA ) labs draw determine serum 25 hydroxyvitamin D , parathyroid hormone , ionized calcium , estradiol , bone-specific acetyl phosphatase , osteocalcin , C-peptides .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Female , age &gt; 18 Able understand give informed consent Relapsing remit multiple sclerosis ( RRMS ) Treatment interferon Copaxone least one year prior study entry Known osteoporosis History hypercalcemia Currently pregnant History primary hyperparathyroidism , hyperthyroidism , hypothyroidism Unstable medical condition Ongoing use bisphosphonates</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>MS ( Multiple Sclerosis )</keyword>
</DOC>